Abstract
Frontal dementia gives rise to characteristic behavioral changes, which include altered emotions, profound alterations in personality and social conduct, and behavioral alterations constitute core and supportive symptoms laid out in the diagnostic criteria. There are some behavioral symptoms which are considered specific for frontal dementia, being present in at least 50% of cases. These includes loss of basic emotions and social embarrassment, selfishness, disinhibition, irritability, neglect, apathy, altered preference for sweet foods, with a tendency to continue eating for as long as food is present, or to steal food from others plates, motor and verbal stereotypies, wandering, and an absence of insightfulness. Albeit anatomical pathways are well known, there is no known therapy to prevent the advance of frontal dementia. The circuits involve a number of transmitters, receptor subtypes, and second messengers that can be potentially mediated pharmacologically. Though, rational treatments are currently limited . We present the possible actual and future therapeutic choices on the basis of anatomical and biochemical substrates.
Keywords: frontal dementia, serotonine, acetylcholine, dopamine
Letters in Drug Design & Discovery
Title: Difficulties in the Management of Frontal Dementia: Therapeutics Strategies
Volume: 2 Issue: 3
Author(s): Rita Moretti, Paola Torre, Rodolfo M. Antonello, Tatiana Cattaruzza and Giuseppe Cazzato
Affiliation:
Keywords: frontal dementia, serotonine, acetylcholine, dopamine
Abstract: Frontal dementia gives rise to characteristic behavioral changes, which include altered emotions, profound alterations in personality and social conduct, and behavioral alterations constitute core and supportive symptoms laid out in the diagnostic criteria. There are some behavioral symptoms which are considered specific for frontal dementia, being present in at least 50% of cases. These includes loss of basic emotions and social embarrassment, selfishness, disinhibition, irritability, neglect, apathy, altered preference for sweet foods, with a tendency to continue eating for as long as food is present, or to steal food from others plates, motor and verbal stereotypies, wandering, and an absence of insightfulness. Albeit anatomical pathways are well known, there is no known therapy to prevent the advance of frontal dementia. The circuits involve a number of transmitters, receptor subtypes, and second messengers that can be potentially mediated pharmacologically. Though, rational treatments are currently limited . We present the possible actual and future therapeutic choices on the basis of anatomical and biochemical substrates.
Export Options
About this article
Cite this article as:
Moretti Rita, Torre Paola, Antonello M. Rodolfo, Cattaruzza Tatiana and Cazzato Giuseppe, Difficulties in the Management of Frontal Dementia: Therapeutics Strategies, Letters in Drug Design & Discovery 2005; 2 (3) . https://dx.doi.org/10.2174/1570180053765147
DOI https://dx.doi.org/10.2174/1570180053765147 |
Print ISSN 1570-1808 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-628X |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
25OH-Vitamin D3 Levels in Obesity and Metabolic Syndrome—Unaltered in Young and not Correlated to Carotid IMT in All Ages
Current Pharmaceutical Design Tailored Multi-Target Agents. Applications and Design Considerations
Current Pharmaceutical Design Insights Into Effects of Ellagic Acid on the Nervous System: A Mini Review
Current Pharmaceutical Design Challenging the Evidence Based Medicine Principles Among Clinical Obesity Treatments
Current Clinical Pharmacology Flavonoids and the Brain: Evidences and Putative Mechanisms for a Protective Capacity
Current Neuropharmacology BioArena Studies: Unique Function of Endogenous Formaldehyde and Ozone in the Antibiotic Effect – A Review
Medicinal Chemistry Na+-H+ Exchanger, pH Regulation and Cancer
Recent Patents on Anti-Cancer Drug Discovery Regulation of βAPP and PrPc Cleavage by α-Secretase: Mechanistic and Therapeutic Perspectives
Current Alzheimer Research Retinoic Acid and the Gut Microbiota in Alzheimer’s Disease: Fighting Back-to-Back?
Current Alzheimer Research Chemical and Medicinal Versatility of Substituted 1,4-Dihydropyridines
Current Bioactive Compounds Neuroimaging Correlates of 22q11.2 Deletion Syndrome: Implications for Schizophrenia Research
Current Topics in Medicinal Chemistry Design, Synthesis and Evaluation of Tacrine Based Acetylcholinesterase Inhibitors
Letters in Drug Design & Discovery Antithrombotic Treatment in the Prevention of Ischemic Stroke
Current Drug Targets Antiviral Treatment of Cytomegalovirus Infection
Infectious Disorders - Drug Targets A Randomized, Double-Blind, Placebo-Controlled Trial of Two Doses of Ginkgo Biloba Extract in Dementia of the Alzheimers Type
Current Alzheimer Research Role of the Transforming-Growth-Factor-β1 Gene in Late-Onset Alzheimer’s Disease: Implications for the Treatment
Current Genomics Insulin Resistance and Alzheimers Disease Pathogenesis: Potential Mechanisms and Implications for Treatment
Current Alzheimer Research Sleep and Antidepressant Treatment
Current Pharmaceutical Design Current Status of Carotid Stenting
Current Vascular Pharmacology Efficacy and Cardiovascular Safety of GLP-1 Receptor Analogues
Current Drug Safety